When was SpyBiotech founded?

SpyBiotech was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is SpyBiotech located?

SpyBiotech is headquartered in Oxford, United Kingdom.

Who is the current CEO of SpyBiotech?

Mark Leuchtenberger of SpyBiotech.

How many employees does SpyBiotech have?

As of Jun 30, 2026, the latest employee count at SpyBiotech is 20.

Is SpyBiotech a funded company?

SpyBiotech is a funded company, having raised a total of $39M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 10, 2017.

How much is SpyBiotech worth?

The latest valuation of SpyBiotech is $***** as of Mar 10, 2017.

When was the latest funding round of SpyBiotech?

SpyBiotech's latest funding was a $***** Grant (prize money) round on Mar 20, 2023, with participation from 1 investor. Its primary sector is Infectious Diseases. In United Kingdom, the Infectious Diseases sector has seen $142M in funding in 2026 to date.

Where does SpyBiotech rank among its competitors?

SpyBiotech ranks 7th amongst 203 active competitors, of which 61 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Basilea, which secured $13.3M in May, 2026.

Who are the top competitors of SpyBiotech?

SpyBiotech's top competitors include ImmunityBio, Insmed and Evofem. Among them, Basilea secured the most recent funding round in May, 2026.

SpyBiotech - 2026 Company Profile, Team, Funding & Competitors

Company Details

SpyBiotech, a spinoff from Oxford University, is developing vaccines for bacterial infections. The company is using its proprietary protein superglue technology which consists of SpyTag (peptide) and SpyCatcher (protein companion) to produce virus-like particles (VLP) vaccines.

Website: spybiotech.com
Social
Email ID: *****@spybiotech.com
Phone Number: +44 **********

Key Metrics

Founded Year

2017

Location

Oxford, United Kingdom

Stage

Series A

Total Funding

$39M in 3 rounds

Latest Funding Round

Grant (prize money), Mar 20, 2023, $*****

Post Money Valuation

$***** as on Mar 10, 2017

Investors

Braavos & 7 more

Ranked

7^th among 203 active competitors

Employee Count

20 as on Jun 30, 2026

Similar Companies

ImmunityBio & 271 more

View SpyBiotech's full profile

SpyBiotech has raised a total funding of $39M over 3 rounds. Its first funding round was on Mar 10, 2017. Its latest funding round was a Grant (prize money) round on Mar 20, 2023 for $*****. 1 investor participated in its latest round. SpyBiotech has 8 institutional investors.

Here is the list of recent funding rounds of SpyBiotech:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 20, 2023	9446565	Grant (prize money)	1515796	7218117	6347106	2965478
Feb 10, 2021	6226556	Series A	5320741	1135755	5533640	Oxford Investment Consultants & 3 more
Mar 10, 2017	7246324	Series A	7434650	9969681	Oxford Science Enterprises	Google Ventures

Access funding benchmarks and valuations. Sign up today!

View details of SpyBiotech's funding rounds and investors

The founders of SpyBiotech are Mark Howarth and Simon Draper. Mark Leuchtenberger is the CEO of SpyBiotech.

Here are the details of SpyBiotech's key team members:

Mark Howarth: Former Co-Founder of SpyBiotech.
Simon Draper: Co-Founder of SpyBiotech.
Mark Leuchtenberger: CEO of SpyBiotech.
Contact Info: 1 email address

SpyBiotech's Board of Directors

SpyBiotech's board has 6 active members. Sumi Biswas is part of team and James Ching Tung Wong, Daniel Menichella, Andre Crawford-brunt, Lutz Giebel and Carolyn Breege Porter are independent board members.

Here is the list of SpyBiotech's board of directors:

Name	Type	Representing	Status	Duration
Sumi Biswas	Team	-	Current	9y 4m
James Ching Tung Wong	Independent board member	-	Current	5y 8m
dbx{yza	Independent board member	-	Current	5y 8m
unqqkux	Independent board member	-	Current	8y 4m
pceffor	Independent board member	-	Current	1y 2m
rknkfv{	Independent board member	-	Current	3y 5m
owcanve	Independent board member	-	Past	5y 5m

View details of SpyBiotech's Founder profiles and Board Members

SpyBiotech's employee count trend

SpyBiotech has 20 employees as of Jun 26. Here is SpyBiotech's employee count trend over the years:

Uncover SpyBiotech's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of SpyBiotech include ImmunityBio, Insmed and Evofem. Here is the list of Top 10 competitors of SpyBiotech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	ImmunityBio 2014, El Segundo (United States), Public	Developer of peptide-based vaccines for immunotherapy	$169M	Oberland Capital, NantWorks & 1 others	67/100
2nd	Insmed 1999, Bridgewater (United States), Public	Developer of small molecule inhibitors for rare lung diseases	-	Foresite Capital, Quaker Partners Management ... & 13 others	66/100
3rd	Evofem 2009, San Diego (United States), Public	Developer of sexual and reproductive health therapeutics	$100M	mercerstcap.com, Aditx Therapeutics & 10 others	65/100
4th	Osivax 2017, Lyon (France), Series B	Developer of vaccines against constantly mutating pathogens	$42.2M	EIC Fund, Noshaq & 10 others	64/100
5th	Brii Biosciences 2018, San Francisco (United States), Public	Developer of biologics to treat hepatitis B infection	$415M	HongShan, Yunfeng Capital & 7 others	63/100
6th	CStone Pharma 2016, Shanghai (China), Public	Developing and licensing novel drugs for diseases including cancer and autoimmune diseases	$410M	GIC, 6 Dimensions Capital & 14 others	59/100
7th	SpyBiotech 2017, Oxford (United Kingdom), Series A	Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology	$39M	Google Ventures, Gates & 6 others	59/100
8th	Basilea 1999, Basel (Switzerland), Public	Developer of antibiotics, antifungals, and oncology drugs for treating multiple diseases	-	Athyrium Capital Management, Medical Countermeasures ... & 2 others	59/100
9th	Centauri Therapeutics 2014, Kent (United Kingdom), Series A	Developer of immunotherapeutics to treat infectious diseases	$73M	Boehringer Ingelheim Venture Fund, REPAIR Impact Fund ... & 32 others	58/100
10th	Diamyd Medical 1994, Stockholm (Sweden), Public	Developer of therapies for the treatment and prevention of autoimmune diabetes	-	UPMC, Innovation Works & 2 others	58/100